WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018007885) COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/007885 International Application No.: PCT/IB2017/053521
Publication Date: 11.01.2018 International Filing Date: 14.06.2017
IPC:
A61K 31/4375 (2006.01) ,A61K 31/4184 (2006.01) ,A61K 39/395 (2006.01) ,A61K 39/00 (2006.01)
Applicants: SONG, Jing[CN/CN]; CN (SC)
WANG, Lai[US/CN]; CN (SC)
BEIGENE, LTD.; c/o Mourant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, KY
Inventors: SONG, Jing; CN
WANG, Lai; CN
LI, Kang; CN
ZHANG, Tong; CN
LUO, Lusong; CN
WEI, Min; CN
TANG, Zhiyu; CN
ZHANG, Guoliang; CN
ZHOU, Changyou; US
Agent: WU, FENG & ZHANG CO.; Room 305, Tower B Beijing Aerospace Cpmiec Building Beijing 100080, CN
Priority Data:
PCT/CN2016/08859105.07.2016CN
Title (EN) COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
(FR) ASSOCIATION D'UN ANTAGONISTE DE PD-1 ET D'UN INHIBITEUR DU RAF POUR LE TRAITEMENT DU CANCER.
Abstract:
(EN) Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.
(FR) L'invention porte sur une combinaison pharmaceutique, présentant une efficacité synergique, destinée à être utilisée dans la prévention, le retard de la progression ou le traitement du cancer, la combinaison pharmaceutique. Elle contient un anticorps monoclonal antagoniste humanisé dirigé contre PD-1 et un inhibiteur de RAF. Une combinaison destinée à être utilisée dans la prévention, le retard de la progression ou le traitement du cancer chez un sujet, comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un anticorps monoclonal antagoniste humanisé contre PD-1 et d'un inhibiteur de RAF.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)